Pain Relief

Dependable Product Profile
Pharmacokinetic Profile
Flexible Dosing
Opioid Conversions
Drug-Drug Interactions

Opana® ER remained effective with stabilized dose
over 12 weeks in clinical trials

Minimal increase in mean pain score (VAS) from baseline to final visit with original formulation:
9 mm vs 32 mm for placebo (P<0.0001)1

Average pain intensity over time for opioid-experienced patients1

In the 12-week treatment phase in 142 opioid-experienced patients
with moderate to severe chronic low back pain1,*

Adverse Events

With Opana® ER, adverse events were similar
to placebo after titration phase

Most common adverse events occurring in opioid-experienced patients2

Adverse Events Across All Clinical Trials

Adverse reactions reported in placebo-controlled
clinical trials (N=5) with incidence ≥2% in patients
receiving Opana® ER2


References

  1. Hale ME, Ahdieh H, Ma T, Rauck R, Oxymorphone ER Study Group 1. Efficacy and safety of OPANA ER (oxymorphone extended release) for relief of moderate to severe chronic low back pain in opioid-experienced patients: a 12-week, randomized, double-blind, placebo-controlled study. J Pain. 2007;8(2):175-184.
  2. Opana® ER (Oxymorphone Hydrochloride) Extended-Release Tablets CII [Prescribing Information]. Endo Pharmaceuticals. Chadds Ford, PA; 2012.